CL2014002846A1 - Usos terapéuticos de proteínas del factor de crecimiento del fibroblasto 21. - Google Patents

Usos terapéuticos de proteínas del factor de crecimiento del fibroblasto 21.

Info

Publication number
CL2014002846A1
CL2014002846A1 CL2014002846A CL2014002846A CL2014002846A1 CL 2014002846 A1 CL2014002846 A1 CL 2014002846A1 CL 2014002846 A CL2014002846 A CL 2014002846A CL 2014002846 A CL2014002846 A CL 2014002846A CL 2014002846 A1 CL2014002846 A1 CL 2014002846A1
Authority
CL
Chile
Prior art keywords
proteins
growth factor
fibroblast growth
therapeutic uses
therapeutic
Prior art date
Application number
CL2014002846A
Other languages
English (en)
Spanish (es)
Inventor
Yanfei Linda Ma
Rovira Armando Rafael Irizarry
Vincent Louis Reynolds
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002846(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2014002846A1 publication Critical patent/CL2014002846A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2014002846A 2012-05-15 2014-10-22 Usos terapéuticos de proteínas del factor de crecimiento del fibroblasto 21. CL2014002846A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261646974P 2012-05-15 2012-05-15
US201361786939P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2014002846A1 true CL2014002846A1 (es) 2015-01-30

Family

ID=48483225

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002846A CL2014002846A1 (es) 2012-05-15 2014-10-22 Usos terapéuticos de proteínas del factor de crecimiento del fibroblasto 21.

Country Status (21)

Country Link
US (1) US20150141335A1 (enExample)
EP (1) EP2852398A1 (enExample)
JP (1) JP2015522539A (enExample)
KR (1) KR20150002801A (enExample)
CN (1) CN104302311A (enExample)
AU (1) AU2013263188A1 (enExample)
BR (1) BR112014028413A2 (enExample)
CA (1) CA2869320A1 (enExample)
CL (1) CL2014002846A1 (enExample)
CO (1) CO7131381A2 (enExample)
EA (1) EA201491856A1 (enExample)
HK (1) HK1202800A1 (enExample)
IL (1) IL235482A0 (enExample)
MA (1) MA37506B1 (enExample)
MX (1) MX2014013913A (enExample)
PE (1) PE20142432A1 (enExample)
PH (1) PH12014502537A1 (enExample)
SG (1) SG11201407655TA (enExample)
TN (1) TN2014000409A1 (enExample)
WO (1) WO2013173158A1 (enExample)
ZA (1) ZA201407532B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
NZ722377A (en) 2014-01-24 2022-09-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10293026B2 (en) 2014-09-08 2019-05-21 Osaka University Agent for preventing or treating demyelinating disease
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
EP4288461A4 (en) 2021-07-14 2025-07-02 Beijing Ql Biopharmaceutical Co Ltd FUSION POLYPEPTIDES FOR METABOLIC DISORDERS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523084A (ja) * 2007-03-30 2010-07-15 アンブルックス,インコーポレイテッド 修飾fgf−21ポリペプチド
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos

Also Published As

Publication number Publication date
JP2015522539A (ja) 2015-08-06
ZA201407532B (en) 2016-05-25
IL235482A0 (en) 2014-12-31
PE20142432A1 (es) 2015-01-22
CA2869320A1 (en) 2013-11-21
KR20150002801A (ko) 2015-01-07
HK1202800A1 (en) 2015-10-09
WO2013173158A1 (en) 2013-11-21
CN104302311A (zh) 2015-01-21
SG11201407655TA (en) 2014-12-30
MX2014013913A (es) 2015-02-17
PH12014502537A1 (en) 2015-01-21
TN2014000409A1 (en) 2015-12-21
CO7131381A2 (es) 2014-12-01
EA201491856A1 (ru) 2015-03-31
MA37506B1 (fr) 2017-03-31
US20150141335A1 (en) 2015-05-21
MA37506A1 (fr) 2016-01-29
BR112014028413A2 (pt) 2017-11-07
EP2852398A1 (en) 2015-04-01
AU2013263188A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
CL2014002846A1 (es) Usos terapéuticos de proteínas del factor de crecimiento del fibroblasto 21.
CO6910165A2 (es) Variantes del factor 21 del crecimiento de fibroblastos
DK2938740T3 (da) Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
EP3679897C0 (en) ADJUSTABLE HEART VALVE IMPLANT
LT3470063T (lt) Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
CL2014002342A1 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma.
DK2940135T5 (da) Heterodimeriseret polypeptid
HRP20182069T1 (hr) Farmaceutski pripravci za liječenje alzheimerove bolesti
DK2863990T3 (da) Medicinsk mikroelektrode
BR112015006198A2 (pt) conjunto de cadeira
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
EP2830533A4 (en) BIOKOMPATIBLE NETWORK IMPLANT
HRP20190318T1 (hr) Farmaceutski ili kozmetički pripravak za liječenje alopecije
EP2906208A4 (en) THERAPEUTIC TREATMENT
LT3292875T (lt) Kompozicijos ir būdai, skirti ligų gydymui
BR112015007861A2 (pt) prótese de tecido
EP2974751A4 (en) HEART OR TISSUE SPHERE
LTPA2020511I1 (lt) Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
HUE051295T2 (hu) Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére
DK2931296T3 (da) Sygdomsbehandling, der involverer mucin
EP2931176A4 (en) Medical sling
HUE043419T2 (hu) Vegyületek remielinizációs blokk kezelésére HERV-W borítékfehérje expresszióval járó betegségekben
CO7131377A2 (es) Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos
IL239078A0 (en) Protein for use in the treatment of eye diseases